National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
NCT Number: NCT02055222
Despite the implementation of modern public health interventions, 1 in 5 adults in the United States are either current or former smokers and remain at risk for the development of chronic lung diseases. It is unknown how or why any one individual smoker can develop a wide range of lung diseases including chronic obstructive lung disease and/or pulmonary fibrosis. The purpose of this protocol is to collect clinical data, blood, urine, and bronchoalveolar samples from smokers and non-smokers in an attempt to establish phenotypic clinical profiles that correspond to divergent pathways in the expression of such proteins as the transforming growth factor-beta1 (TGF-beta <=1). The information generated from this study will provide insight into the pathogenesis of smoking-related lung injury and potentially allow for the development of early therapeutic interventions.
Looking for future studies?
Notify Me40 year–80 year
All sexes
Observational
Bethesda, Maryland, 20892, United States
Despite the implementation of modern public health interventions, 1 in 5 adults in the United States are either current or former smokers and remain at risk for the development of chronic lung diseases. It is unknown how or why any one individual smoker can develop a wide range of lung diseases including chronic obstructive lung disease and/or pulmonary fibrosis. The purpose of this protocol is to collect clinical data, blood, urine, and bronchoalveolar samples from smokers and non-smokers in an attempt to establish phenotypic clinical profiles that correspond to divergent pathways in the expression of such proteins as the transforming growth factor-beta1 (TGF-beta1). The information generated from this study will provide insight into the pathogenesis of smoking-related lung injury and potentially allow for the development of early therapeutic interventions.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Exclusion criteria
For subjects with lung diseases:
Subjects will be excluded from the study if they meet one or more of the following criteria:
Inclusion criteria
For Non-Smoking Controls
Exclusion criteria
For Non-Smoking Controls
Inclusion criteria
For Smoking Controls
Exclusion criteria
For Smoking Controls
Time frame: 3 years
Determine changes in validated clinical parameters of smokers with interstitial lung abnormalities (ILA) as compared to controls and patients with IPF and COPD
National Heart, Lung, and Blood Institute (NHLBI)
Nih
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00052052
Fibrosis, Idiopathic Pulmonary Fibrosis
Seattle, Washington, United States
View Trial DetailsNCT00131274
Fibrosis, Idiopathic Pulmonary Fibrosis
View Trial DetailsNCT06160440
Diopathic Pulmonary Fibrosis, Fibrosis
Guangzhou, Guangdong, China
View Trial DetailsNCT01442779
Fibrosis, Idiopathic Pulmonary Fibrosis
Lubbock, Texas, United States
View Trial Details